Genetic Diagnosis of Retinoblastoma Using Aqueous Humour—Findings from an Extended Cohort
Author:
Gerrish Amy1ORCID, Mashayamombe-Wolfgarten Chipo1ORCID, Stone Edward12, Román-Montañana Claudia1, Abbott Joseph3, Jenkinson Helen3, Millen Gerard3, Gurney Sam3ORCID, McCalla Maureen3, Staveley Sarah-Jane3, Kainth Anu3, Kirk Maria3, Bowen Claire4, Cavanagh Susan4, Bunstone Sancha2, Carney Megan2, Mohite Ajay3ORCID, Clokie Samuel1, Reddy M. Ashwin5ORCID, Foster Alison1, Allen Stephanie1, Parulekar Manoj3, Cole Trevor1
Affiliation:
1. West Midlands Regional Genetics Service, Birmingham Women’s Hospital, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham B15 2TG, UK 2. North West Genomic Laboratory Hub (Manchester), St Mary’s Hospital, Manchester University NHS Foundation Trust, Manchester M13 9WL, UK 3. Birmingham Children’s Hospital Eye Department, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham B4 6NH, UK 4. Birmingham Children’s Hospital Histopathology Department, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham B4 6NH, UK 5. Retinoblastoma Unit, Royal London Hospital, Barts Health NHS Trust, London E1 1BB, UK
Abstract
The identification of somatic RB1 variation is crucial to confirm the heritability of retinoblastoma. We and others have previously shown that, when tumour DNA is unavailable, cell-free DNA (cfDNA) derived from aqueous humour (AH) can be used to identify somatic RB1 pathogenic variation. Here we report RB1 pathogenic variant detection, as well as cfDNA concentration in an extended cohort of 75 AH samples from 68 patients. We show cfDNA concentration is highly variable and significantly correlated with the collection point of the AH. Cell-free DNA concentrations above 5 pg/µL enabled the detection of 93% of known or expected RB1 pathogenic variants. In AH samples collected during intravitreal chemotherapy treatment (Tx), the yield of cfDNA above 5 pg/µL and subsequent variant detection was low (≤46%). However, AH collected by an anterior chamber tap after one to three cycles of primary chemotherapy (Dx1+) enabled the detection of 75% of expected pathogenic variants. Further limiting our analysis to Dx1+ samples taken after ≤2 cycles (Dx ≤ 2) provided measurable levels of cfDNA in all cases, and a subsequent variant detection rate of 95%. Early AH sampling is therefore likely to be important in maximising cfDNA concentration and the subsequent detection of somatic RB1 pathogenic variants in retinoblastoma patients undergoing conservative treatment.
Funder
Fight for Sight Fight for Sight & Childhood Eye Cancer Trust Birmingham Women’s and Children’s NHS Foundation Trust The Wellcome Trust
Reference43 articles.
1. Pagon, R.A., Adam, M.P., Ardinger, H.H., Wallace, S.E., Amemiya, A., Bean, L.J., Bird, T.D., Fong, C.-T., Mefford, H.C., and Smith, R.J. (1993). GeneReviews(®), University of Washington. 2. Spectrum of RB1 Mutations Identified in 403 Retinoblastoma Patients;Price;J. Med. Genet.,2014 3. RB1 Mutation Spectrum in a Comprehensive Nationwide Cohort of Retinoblastoma Patients;Dommering;J. Med. Genet.,2014 4. Mutation and Cancer: Statistical Study of Retinoblastoma;Knudson;Proc. Natl. Acad. Sci. USA,1971 5. Characterisation of Retinoblastomas without RB1 Mutations: Genomic, Gene Expression, and Clinical Studies;Rushlow;Lancet Oncol.,2013
|
|